On August 20, Moderna, Inc. declined 4.66% overnight, trading at $166.29/share, with turnover of $821,700. The pullback follows the stock's record-breaking 177% single-day surge during the prior session, which added approximately $44 billion in market capitalization.

The historic rally was driven by Moderna and Merck's announcement that their personalized mRNA cancer vaccine intismeran autogene achieved positive results in the Phase III Interpath-001 trial, meeting both the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in completely resected stage IIB-IV melanoma patients. This marked the first successful Phase III trial for any mRNA-based cancer therapy.

The overnight retracement appears linked to profit-taking as the stock traded above several newly raised analyst price targets. Following the data release, Goldman Sachs raised its target to $120, Piper Sandler to $167, and BofA Securities to $170 — all near or below the prior close of approximately $174. Short sellers had already faced an estimated $4.8 billion in mark-to-market losses during the rally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)